Cargando…
Chloroquine/dalteparin sodium/hydroxycarbamide: Prolongation of the QTc interval secondary to off-label use and lack of efficacy: case report
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298963/ http://dx.doi.org/10.1007/s40278-021-99424-1 |
Ejemplares similares
-
Chloroquine: QTc prolongation following off-label use: case report
Publicado: (2022) -
QTc interval prolongation, COVID-19 and chloroquine
por: Wiwanitkit, V.
Publicado: (2020) -
Gilteritinib/hydroxycarbamide/remdesivir: Neutropenia, lack of efficacy and off-label use: case report
Publicado: (2021) -
Chloroquine/lopinavir/ritonavir/umifenovir: QTc interval prolongation, drug interaction and off-label use: 2 case reports
Publicado: (2020) -
Chloroquine: QTc interval prolongation leading to frequent extrasystoles and ventricular tachycardia following off label use: case report
Publicado: (2021)